▶ 調査レポート

ポックスウイルス感染症治療薬の世界市場レポート2020

• 英文タイトル:Global Poxviridae Infections Drug Sales Market Report 2020

が調査・発行した産業分析レポートです。ポックスウイルス感染症治療薬の世界市場レポート2020 / Global Poxviridae Infections Drug Sales Market Report 2020 / MRC2102QY11476資料のイメージです。• レポートコード:MRC2102QY11476
• 出版社/出版日: / 2021年1月
• レポート形態:英文、PDF、149ページ
• 納品方法:Eメール(受注後2~3営業日)
• 産業分類:医薬品、医療
• 販売価格(消費税別)
  Single User¥592,000 (USD4,000)▷ お問い合わせ
  Multi User¥888,000 (USD6,000)▷ お問い合わせ
  Enterprise License¥1,184,000 (USD8,000)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
QYリサーチ社の本調査レポートでは、世界のポックスウイルス感染症治療薬市場について種類別(CJ-40011、24a、BA-368、その他)、用途別(病院、診療所、その他)、地域別(米国、ヨーロッパ、中国、日本、東南アジア、インド)に区分して調査し、纏めました。2015年~2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。
・ポックスウイルス感染症治療薬市場の概要
・世界の主要地域別ポックスウイルス感染症治療薬市場規模2015-2026
・主要プレイヤーの競争状況・市場シェア
・世界のポックスウイルス感染症治療薬市場規模2015-2026:種類別(CJ-40011、24a、BA-368、その他)
・世界のポックスウイルス感染症治療薬市場規模2015-2026:用途別(病院、診療所、その他)
・ポックスウイルス感染症治療薬の米国市場規模2015-2020
・ポックスウイルス感染症治療薬のヨーロッパ市場規模2015-2020
・ポックスウイルス感染症治療薬の中国市場規模2015-2020
・ポックスウイルス感染症治療薬の日本市場規模2015-2020
・ポックスウイルス感染症治療薬の東南アジア市場規模2015-2020
・ポックスウイルス感染症治療薬のインド市場規模2015-2020
・主要プレイヤーの企業情報:事業概要・売上・企業動向
・ポックスウイルス感染症治療薬の製造コスト分析
・販売チャネル、流通業者、顧客
・ポックスウイルス感染症治療薬の市場動向・機会・課題
・調査の結論

Market Analysis and Insights: Global Poxviridae Infections Drug Market
The global Poxviridae Infections Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.

Global Poxviridae Infections Drug Scope and Market Size
The global Poxviridae Infections Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Poxviridae Infections Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.

Segment by Type, the Poxviridae Infections Drug market is segmented into
CJ-40011
24a
BA-368
Others

Segment by Application, the Poxviridae Infections Drug market is segmented into
Hospital
Clinic
Others

The Poxviridae Infections Drug market is analysed and market size information is provided by regions (countries). Segment by Application, the Poxviridae Infections Drug market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Poxviridae Infections Drug Market Share Analysis
Poxviridae Infections Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Poxviridae Infections Drug business, the date to enter into the Poxviridae Infections Drug market, Poxviridae Infections Drug product introduction, recent developments, etc.

The major vendors covered:
Bavarian Nordic A/S
BioFactura, Inc.
CEL-SCI Corporation
Chimerix, Inc.
China Biologic Products, Inc.
CJ HealthCare Corp.
EpiVax, Inc.
N & N Pharmaceuticals Inc.
SIGA Technologies, Inc.
Takeda Pharmaceutical Company Limited
Tonix Pharmaceuticals Holding Corp.
Verrica Pharmaceuticals Inc.

レポート目次

1 Poxviridae Infections Drug Market Overview
1.1 Poxviridae Infections Drug Product Scope
1.2 Poxviridae Infections Drug Segment by Type
1.2.1 Global Poxviridae Infections Drug Sales by Type (2020-2026)
1.2.2 CJ-40011
1.2.3 24a
1.2.4 BA-368
1.2.5 Others
1.3 Poxviridae Infections Drug Segment by Application
1.3.1 Global Poxviridae Infections Drug Sales Comparison by Application (2020-2026)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Poxviridae Infections Drug Market Estimates and Forecasts (2015-2026)
1.4.1 Global Poxviridae Infections Drug Sales Growth Rate (2015-2026)
1.4.2 Global Poxviridae Infections Drug Revenue and Growth Rate (2015-2026)
1.4.3 Global Poxviridae Infections Drug Price Trends (2015-2026)

2 Poxviridae Infections Drug Estimate and Forecast by Region
2.1 Global Poxviridae Infections Drug Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Poxviridae Infections Drug Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Poxviridae Infections Drug Sales Market Share by Region (2015-2020)
2.2.2 Global Poxviridae Infections Drug Revenue Market Share by Region (2015-2020)
2.3 Global Poxviridae Infections Drug Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Poxviridae Infections Drug Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Poxviridae Infections Drug Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Poxviridae Infections Drug Estimates and Projections (2015-2026)
2.4.2 Europe Poxviridae Infections Drug Estimates and Projections (2015-2026)
2.4.3 China Poxviridae Infections Drug Estimates and Projections (2015-2026)
2.4.4 Japan Poxviridae Infections Drug Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Poxviridae Infections Drug Estimates and Projections (2015-2026)
2.4.6 India Poxviridae Infections Drug Estimates and Projections (2015-2026)
3 Global Poxviridae Infections Drug Competition Landscape by Players
3.1 Global Top Poxviridae Infections Drug Players by Sales (2015-2020)
3.2 Global Top Poxviridae Infections Drug Players by Revenue (2015-2020)
3.3 Global Poxviridae Infections Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Poxviridae Infections Drug as of 2019)
3.4 Global Poxviridae Infections Drug Average Price by Company (2015-2020)
3.5 Manufacturers Poxviridae Infections Drug Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Poxviridae Infections Drug Players (Opinion Leaders)
4 Global Poxviridae Infections Drug Market Size by Type
4.1 Global Poxviridae Infections Drug Historic Market Review by Type (2015-2020)
4.1.1 Global Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
4.1.2 Global Poxviridae Infections Drug Revenue Market Share by Type (2015-2020)
4.1.3 Global Poxviridae Infections Drug Price by Type (2015-2020)
4.2 Global Poxviridae Infections Drug Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Poxviridae Infections Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Poxviridae Infections Drug Revenue Forecast by Type (2021-2026)
4.2.3 Global Poxviridae Infections Drug Price Forecast by Type (2021-2026)
5 Global Poxviridae Infections Drug Market Size by Application
5.1 Global Poxviridae Infections Drug Historic Market Review by Application (2015-2020)
5.1.1 Global Poxviridae Infections Drug Sales Market Share by Application (2015-2020)
5.1.2 Global Poxviridae Infections Drug Revenue Market Share by Application (2015-2020)
5.1.3 Global Poxviridae Infections Drug Price by Application (2015-2020)
5.2 Global Poxviridae Infections Drug Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Poxviridae Infections Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Poxviridae Infections Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Poxviridae Infections Drug Price Forecast by Application (2021-2026)

6 United States Poxviridae Infections Drug Market Facts & Figures
6.1 United States Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
6.2 United States Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
6.3 United States Poxviridae Infections Drug Sales Market Share by Application (2015-2020)

7 Europe Poxviridae Infections Drug Market Facts & Figures
7.1 Europe Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
7.2 Europe Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
7.3 Europe Poxviridae Infections Drug Sales Market Share by Application (2015-2020)

8 China Poxviridae Infections Drug Market Facts & Figures
8.1 China Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
8.2 China Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
8.3 China Poxviridae Infections Drug Sales Market Share by Application (2015-2020)

9 Japan Poxviridae Infections Drug Market Facts & Figures
9.1 Japan Poxviridae Infections Drug Sales Market Share by Company (3015-3030)
9.2 Japan Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
9.3 Japan Poxviridae Infections Drug Sales Market Share by Application (2015-2020)

10 Southeast Asia Poxviridae Infections Drug Market Facts & Figures
10.1 Southeast Asia Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
10.2 Southeast Asia Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
10.3 Southeast Asia Poxviridae Infections Drug Sales Market Share by Application (2015-2020)

11 India Poxviridae Infections Drug Market Facts & Figures
11.1 India Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
11.2 India Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
11.3 India Poxviridae Infections Drug Sales Market Share by Application (2015-2020)

12 Company Profiles and Key Figures in Poxviridae Infections Drug Business
12.1 Bavarian Nordic A/S
12.1.1 Bavarian Nordic A/S Corporation Information
12.1.2 Bavarian Nordic A/S Business Overview
12.1.3 Bavarian Nordic A/S Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Bavarian Nordic A/S Poxviridae Infections Drug Products Offered
12.1.5 Bavarian Nordic A/S Recent Development
12.2 BioFactura, Inc.
12.2.1 BioFactura, Inc. Corporation Information
12.2.2 BioFactura, Inc. Business Overview
12.2.3 BioFactura, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.2.4 BioFactura, Inc. Poxviridae Infections Drug Products Offered
12.2.5 BioFactura, Inc. Recent Development
12.3 CEL-SCI Corporation
12.3.1 CEL-SCI Corporation Corporation Information
12.3.2 CEL-SCI Corporation Business Overview
12.3.3 CEL-SCI Corporation Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.3.4 CEL-SCI Corporation Poxviridae Infections Drug Products Offered
12.3.5 CEL-SCI Corporation Recent Development
12.4 Chimerix, Inc.
12.4.1 Chimerix, Inc. Corporation Information
12.4.2 Chimerix, Inc. Business Overview
12.4.3 Chimerix, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Chimerix, Inc. Poxviridae Infections Drug Products Offered
12.4.5 Chimerix, Inc. Recent Development
12.5 China Biologic Products, Inc.
12.5.1 China Biologic Products, Inc. Corporation Information
12.5.2 China Biologic Products, Inc. Business Overview
12.5.3 China Biologic Products, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.5.4 China Biologic Products, Inc. Poxviridae Infections Drug Products Offered
12.5.5 China Biologic Products, Inc. Recent Development
12.6 CJ HealthCare Corp.
12.6.1 CJ HealthCare Corp. Corporation Information
12.6.2 CJ HealthCare Corp. Business Overview
12.6.3 CJ HealthCare Corp. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.6.4 CJ HealthCare Corp. Poxviridae Infections Drug Products Offered
12.6.5 CJ HealthCare Corp. Recent Development
12.7 EpiVax, Inc.
12.7.1 EpiVax, Inc. Corporation Information
12.7.2 EpiVax, Inc. Business Overview
12.7.3 EpiVax, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.7.4 EpiVax, Inc. Poxviridae Infections Drug Products Offered
12.7.5 EpiVax, Inc. Recent Development
12.8 N & N Pharmaceuticals Inc.
12.8.1 N & N Pharmaceuticals Inc. Corporation Information
12.8.2 N & N Pharmaceuticals Inc. Business Overview
12.8.3 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.8.4 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Products Offered
12.8.5 N & N Pharmaceuticals Inc. Recent Development
12.9 SIGA Technologies, Inc.
12.9.1 SIGA Technologies, Inc. Corporation Information
12.9.2 SIGA Technologies, Inc. Business Overview
12.9.3 SIGA Technologies, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.9.4 SIGA Technologies, Inc. Poxviridae Infections Drug Products Offered
12.9.5 SIGA Technologies, Inc. Recent Development
12.10 Takeda Pharmaceutical Company Limited
12.10.1 Takeda Pharmaceutical Company Limited Corporation Information
12.10.2 Takeda Pharmaceutical Company Limited Business Overview
12.10.3 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Products Offered
12.10.5 Takeda Pharmaceutical Company Limited Recent Development
12.11 Tonix Pharmaceuticals Holding Corp.
12.11.1 Tonix Pharmaceuticals Holding Corp. Corporation Information
12.11.2 Tonix Pharmaceuticals Holding Corp. Business Overview
12.11.3 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Products Offered
12.11.5 Tonix Pharmaceuticals Holding Corp. Recent Development
12.12 Verrica Pharmaceuticals Inc.
12.12.1 Verrica Pharmaceuticals Inc. Corporation Information
12.12.2 Verrica Pharmaceuticals Inc. Business Overview
12.12.3 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Products Offered
12.12.5 Verrica Pharmaceuticals Inc. Recent Development

13 Poxviridae Infections Drug Manufacturing Cost Analysis
13.1 Poxviridae Infections Drug Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Poxviridae Infections Drug
13.4 Poxviridae Infections Drug Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Poxviridae Infections Drug Distributors List
14.3 Poxviridae Infections Drug Customers

15 Market Dynamics
15.1 Poxviridae Infections Drug Market Trends
15.2 Poxviridae Infections Drug Opportunities and Drivers
15.3 Poxviridae Infections Drug Market Challenges
15.4 Poxviridae Infections Drug Market Restraints
15.5 Porter’s Five Forces Analysis

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

List of Tables
Table 1. Global Poxviridae Infections Drug Sales (K Pcs) Growth Rate by Type (2020-2026) (US$ Million)
Table 2. Global Poxviridae Infections Drug Sales (K Pcs) Comparison by Application (2020-2026) (US$ Million)
Table 3. Global Market Poxviridae Infections Drug Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Poxviridae Infections Drug Sales (K Pcs) by Region (2015-2020)
Table 5. Global Poxviridae Infections Drug Sales Market Share by Region (2015-2020)
Table 6. Global Poxviridae Infections Drug Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Poxviridae Infections Drug Revenue Share by Region (2015-2020)
Table 8. Global Poxviridae Infections Drug Sales (K Pcs) Forecast by Region (2021-2026)
Table 9. Global Poxviridae Infections Drug Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Poxviridae Infections Drug Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Poxviridae Infections Drug Revenue Share Forecast by Region (2021-2026)
Table 12. Global Poxviridae Infections Drug (K Pcs) of Key Companies (2015-2020)
Table 13. Global Poxviridae Infections Drug Sales Share by Company (2015-2020)
Table 14. Global Poxviridae Infections Drug Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Poxviridae Infections Drug Revenue Share by Company (2015-2020)
Table 16. Global Poxviridae Infections Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Poxviridae Infections Drug as of 2019)
Table 17. Global Poxviridae Infections Drug Average Price (USD/Pcs) of Key Company (2015-2020)
Table 18. Manufacturers Poxviridae Infections Drug Manufacturing Sites and Area Served
Table 19. Manufacturers Poxviridae Infections Drug Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Poxviridae Infections Drug Players
Table 22. Global Poxviridae Infections Drug Sales (K Pcs) by Type (2015-2020)
Table 23. Global Poxviridae Infections Drug Sales Share by Type (2015-2020)
Table 24. Global Poxviridae Infections Drug Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Poxviridae Infections Drug Price (K Pcs) by Type (2015-2020)
Table 26. Global Poxviridae Infections Drug Sales Share by Type (2021-2026)
Table 27. Global Poxviridae Infections Drug Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Poxviridae Infections Drug Revenue Share by Type (2021-2026)
Table 29. Global Poxviridae Infections Drug Price (K Pcs) by Type (2021-2026)
Table 30. Global Poxviridae Infections Drug Sales (K Pcs) by Application (2015-2020)
Table 31. Global Poxviridae Infections Drug Sales Share by Application (2015-2020)
Table 32. Global Poxviridae Infections Drug Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Poxviridae Infections Drug Price (K Pcs) by Application (2015-2020)
Table 34. Global Poxviridae Infections Drug Sales (K Pcs) by Application (2021-2026)
Table 35. Global Poxviridae Infections Drug Sales Share by Application (2021-2026)
Table 36. Global Poxviridae Infections Drug Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Poxviridae Infections Drug Revenue Share by Application (2021-2026)
Table 38. Global Poxviridae Infections Drug Price (K Pcs) by Application (2021-2026)
Table 39. United States Poxviridae Infections Drug Sales (K Pcs) by Company (2015-2020)
Table 40. United States Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
Table 41. United States Poxviridae Infections Drug Sales (K Pcs) by Type (2015-2020)
Table 42. United States Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
Table 43. United States Poxviridae Infections Drug Sales (K Pcs) by Application (2015-2020)
Table 44. United States Poxviridae Infections Drug Sales Market Share by Application (2015-2020)
Table 45. Europe Poxviridae Infections Drug Sales (K Pcs) by Company (2015-2020)
Table 46. Europe Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
Table 47. Europe Poxviridae Infections Drug Sales (K Pcs) by Type (2015-2020)
Table 48. Europe Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
Table 49. Europe Poxviridae Infections Drug Sales (K Pcs) by Application (2015-2020)
Table 50. Europe Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
Table 51. China Poxviridae Infections Drug Sales (K Pcs) by Company (2015-2020)
Table 52. China Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
Table 53. China Poxviridae Infections Drug Sales (K Pcs) by Type (2015-2020)
Table 54. China Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
Table 55. China Poxviridae Infections Drug Sales (K Pcs) by Application (2015-2020)
Table 56. China Poxviridae Infections Drug Sales Market Share by Application (2015-2020)
Table 57. Japan Poxviridae Infections Drug Sales (K Pcs) by Company (2015-2020)
Table 58. Japan Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
Table 59. Japan Poxviridae Infections Drug Sales (K Pcs) by Type (2015-2020)
Table 60. Japan Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
Table 61. Japan Poxviridae Infections Drug Sales (K Pcs) by Application (2015-2020)
Table 62. Japan Poxviridae Infections Drug Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Poxviridae Infections Drug Sales (K Pcs) by Company (2015-2020)
Table 64. Southeast Asia Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Poxviridae Infections Drug Sales (K Pcs) by Type (2015-2020)
Table 66. Southeast Asia Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Poxviridae Infections Drug Sales (K Pcs) by Type (2015-2020)
Table 68. Southeast Asia Poxviridae Infections Drug Sales Market Share by Application (2015-2020)
Table 69. India Poxviridae Infections Drug Sales (K Pcs) by Company (2015-2020)
Table 70. India Poxviridae Infections Drug Sales Market Share by Company (2015-2020)
Table 71. India Poxviridae Infections Drug Sales (K Pcs) by Type (2015-2020)
Table 72. India Poxviridae Infections Drug Sales Market Share by Type (2015-2020)
Table 73. India Poxviridae Infections Drug Sales (K Pcs) by Application (2015-2020)
Table 74. India Poxviridae Infections Drug Sales Market Share by Application (2015-2020)
Table 75. Bavarian Nordic A/S Corporation Information
Table 76. Bavarian Nordic A/S Description and Business Overview
Table 77. Bavarian Nordic A/S Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Bavarian Nordic A/S Poxviridae Infections Drug Product
Table 79. Bavarian Nordic A/S Recent Development
Table 80. BioFactura, Inc. Corporation Information
Table 81. BioFactura, Inc. Description and Business Overview
Table 82. BioFactura, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. BioFactura, Inc. Poxviridae Infections Drug Product
Table 84. BioFactura, Inc. Recent Development
Table 85. CEL-SCI Corporation Corporation Information
Table 86. CEL-SCI Corporation Description and Business Overview
Table 87. CEL-SCI Corporation Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. CEL-SCI Corporation Poxviridae Infections Drug Product
Table 89. CEL-SCI Corporation Recent Development
Table 90. Chimerix, Inc. Corporation Information
Table 91. Chimerix, Inc. Description and Business Overview
Table 92. Chimerix, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. Chimerix, Inc. Poxviridae Infections Drug Product
Table 94. Chimerix, Inc. Recent Development
Table 95. China Biologic Products, Inc. Corporation Information
Table 96. China Biologic Products, Inc. Description and Business Overview
Table 97. China Biologic Products, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. China Biologic Products, Inc. Poxviridae Infections Drug Product
Table 99. China Biologic Products, Inc. Recent Development
Table 100. CJ HealthCare Corp. Corporation Information
Table 101. CJ HealthCare Corp. Description and Business Overview
Table 102. CJ HealthCare Corp. Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. CJ HealthCare Corp. Poxviridae Infections Drug Product
Table 104. CJ HealthCare Corp. Recent Development
Table 105. EpiVax, Inc. Corporation Information
Table 106. EpiVax, Inc. Description and Business Overview
Table 107. EpiVax, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. EpiVax, Inc. Poxviridae Infections Drug Product
Table 109. EpiVax, Inc. Recent Development
Table 110. N & N Pharmaceuticals Inc. Corporation Information
Table 111. N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 112. N & N Pharmaceuticals Inc. Description and Business Overview
Table 113. N & N Pharmaceuticals Inc. Poxviridae Infections Drug Product
Table 114. N & N Pharmaceuticals Inc. Recent Development
Table 115. SIGA Technologies, Inc. Corporation Information
Table 116. SIGA Technologies, Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 117. SIGA Technologies, Inc. Description and Business Overview
Table 118. SIGA Technologies, Inc. Poxviridae Infections Drug Product
Table 119. SIGA Technologies, Inc. Recent Development
Table 120. Takeda Pharmaceutical Company Limited Corporation Information
Table 121. Takeda Pharmaceutical Company Limited Description and Business Overview
Table 122. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 123. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product
Table 124. Takeda Pharmaceutical Company Limited Recent Development
Table 125. Tonix Pharmaceuticals Holding Corp. Corporation Information
Table 126. Tonix Pharmaceuticals Holding Corp. Description and Business Overview
Table 127. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 128. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product
Table 129. Tonix Pharmaceuticals Holding Corp. Recent Development
Table 130. Verrica Pharmaceuticals Inc. Corporation Information
Table 131. Verrica Pharmaceuticals Inc. Description and Business Overview
Table 132. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 133. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product
Table 134. Verrica Pharmaceuticals Inc. Recent Development
Table 135. Production Base and Market Concentration Rate of Raw Material
Table 136. Key Suppliers of Raw Materials
Table 137. Poxviridae Infections Drug Distributors List
Table 138. Poxviridae Infections Drug Customers List
Table 139. Poxviridae Infections Drug Market Key Trends
Table 140. Poxviridae Infections Drug Key Opportunities and Drivers
Table 141. Poxviridae Infections Drug Market Challenges
Table 142. Research Programs/Design for This Report
Table 143. Key Data Information from Secondary Sources
Table 144. Key Data Information from Primary Sources
List of Figures
Figure 1. Poxviridae Infections Drug Product Picture
Figure 2. Global Poxviridae Infections Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Poxviridae Infections Drug Market Share by Application in 2020 & 2026
Figure 6. Hospital Examples
Figure 7. Clinic Examples
Figure 8. Others Examples
Figure 9. Global Poxviridae Infections Drug Sales (K Pcs) Growth Rate (2015-2026)
Figure 10. Global Poxviridae Infections Drug Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Poxviridae Infections Drug Price Trends Growth Rate (2015-2026) (USD/Pcs)
Figure 12. Global Poxviridae Infections Drug Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Poxviridae Infections Drug Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Poxviridae Infections Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Poxviridae Infections Drug Sales (K Pcs) Growth Rate (2015-2026)
Figure 16. Europe Poxviridae Infections Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Poxviridae Infections Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Poxviridae Infections Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Poxviridae Infections Drug Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Poxviridae Infections Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Poxviridae Infections Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Poxviridae Infections Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Poxviridae Infections Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Poxviridae Infections Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Poxviridae Infections Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Poxviridae Infections Drug Players Market Share by Revenue in Poxviridae Infections Drug 2015 & 2019
Figure 27. Poxviridae Infections Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Poxviridae Infections Drug Revenue Share by Type (2015-2020)
Figure 29. Global Poxviridae Infections Drug Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Poxviridae Infections Drug Revenue Share by Application (2015-2020)
Figure 31. Global Poxviridae Infections Drug Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Poxviridae Infections Drug Sales Market Share by Type in 2019
Figure 33. United States Poxviridae Infections Drug Sales Market Share by Type in 2019
Figure 34. Europe Poxviridae Infections Drug Sales Market Share by Company in 2019
Figure 35. Europe Poxviridae Infections Drug Sales Market Share by Type in 2019
Figure 36. Europe Poxviridae Infections Drug Sales Market Share by Application in 2019
Figure 37. China Poxviridae Infections Drug Sales Market Share by Company in 2019
Figure 38. China Poxviridae Infections Drug Sales Market Share by Type in 2019
Figure 39. China Poxviridae Infections Drug Sales Market Share by Application in 2019
Figure 40. Japan Poxviridae Infections Drug Sales Market Share by Company in 2019
Figure 41. Japan Poxviridae Infections Drug Sales Market Share by Type in 2019
Figure 42. Japan Poxviridae Infections Drug Sales Market Share by Application in 2019
Figure 43. Southeast Asia Poxviridae Infections Drug Sales Market Share by Company in 2019
Figure 44. Southeast Asia Poxviridae Infections Drug Sales Market Share by Type in 2019
Figure 45. Southeast Asia Poxviridae Infections Drug Sales Market Share by Application in 2019
Figure 46. India Poxviridae Infections Drug Sales Market Share by Company in 2019
Figure 47. India Poxviridae Infections Drug Sales Market Share by Type in 2019
Figure 48. India Poxviridae Infections Drug Sales Market Share by Application in 2019
Figure 49. Key Raw Materials Price Trend
Figure 50. Manufacturing Cost Structure of Poxviridae Infections Drug
Figure 51. Manufacturing Process Analysis of Poxviridae Infections Drug
Figure 52. Poxviridae Infections Drug Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Porter's Five Forces Analysis
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed